Profil
Jean-Marc Le Doussal is the founder.
He founded Remora Capital SA in 2009 and currently holds the title of Managing Partner.
He is also currently the President of OGD2 Pharma SAS.
In the past, he served as the Chairman of Telix Pharmaceuticals SAS.
Aktive Positionen von Jean-Marc Le Doussal
| Unternehmen | Position | Beginn |
|---|---|---|
Remora Capital SA
 Remora Capital SA Investment ManagersFinance Remora Capital SA (Remora Capital) is a venture capital firm founded by Dr. Jean-Marc Le Doussal in 2009. The firm is headquartered in Switzerland. | Gründer | 22.09.2009 |
OGD2 Pharma SAS
 OGD2 Pharma SAS BiotechnologyHealth Technology OGD2 Pharma SAS develops and commercializes anti-GD2 cancer immunotherapies that target O-acetylated-GD2. The firm continues exploring the potential of therapies targeting the OAcGD2 antigen in various cancers. The company is headquartered in Nantes, France. | Präsident | - |
Ehemalige bekannte Positionen von Jean-Marc Le Doussal
| Unternehmen | Position | Ende |
|---|---|---|
Telix Pharmaceuticals SAS
 Telix Pharmaceuticals SAS BiotechnologyHealth Technology Telix Pharmaceuticals SAS engages in the pharmaceutical industry. It provides research in biotechnology. The company was founded on July 25, 2008 and is headquartered in Nantes, France. | Vorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Remora Capital SA
Remora Capital SA Investment ManagersFinance Remora Capital SA (Remora Capital) is a venture capital firm founded by Dr. Jean-Marc Le Doussal in 2009. The firm is headquartered in Switzerland. | Finance |
OGD2 Pharma SAS
OGD2 Pharma SAS BiotechnologyHealth Technology OGD2 Pharma SAS develops and commercializes anti-GD2 cancer immunotherapies that target O-acetylated-GD2. The firm continues exploring the potential of therapies targeting the OAcGD2 antigen in various cancers. The company is headquartered in Nantes, France. | Health Technology |
Telix Pharmaceuticals SAS
Telix Pharmaceuticals SAS BiotechnologyHealth Technology Telix Pharmaceuticals SAS engages in the pharmaceutical industry. It provides research in biotechnology. The company was founded on July 25, 2008 and is headquartered in Nantes, France. | Health Technology |
